Mounjaro is tirzepatide (Eli Lilly); Ozempic is semaglutide (Novo Nordisk). Both are once-weekly injections FDA-approved for type 2 diabetes, and both are prescribed off-label for weight loss. In the head-to-head SURPASS-2 diabetes trial, tirzepatide produced greater A1c and weight reductions than semaglutide. That said, the "right" drug depends on individual response, side-effect tolerance, insurance and cost — this is general education, and the decision belongs to you and your clinician.
Key takeaways
- Mounjaro = tirzepatide (dual GIP/GLP-1, Eli Lilly); Ozempic = semaglutide (GLP-1, Novo Nordisk).
- Both are once-weekly injections FDA-approved for type 2 diabetes, and both are used off-label for weight loss.
- In the head-to-head SURPASS-2 trial, tirzepatide beat semaglutide on A1c and weight reduction.
- The dedicated weight-management approvals belong to their siblings — Zepbound and Wegovy.
What's the difference between Mounjaro and Ozempic?
The two are related cousins, not twins. Mounjaro is tirzepatide, a dual agonist that activates both the GIP and GLP-1 receptors. Ozempic is semaglutide, which activates the GLP-1 receptor alone. Both slow gastric emptying, improve insulin response and reduce appetite, but tirzepatide's second receptor target is the mechanistic reason it tends to edge out semaglutide on blood-sugar and weight in studies.
Importantly, both Mounjaro and Ozempic are approved for the same primary purpose: managing blood sugar in type 2 diabetes. Neither is FDA-approved for weight loss — that's what their sibling brands, Zepbound and Wegovy, are for. When people take Mounjaro or Ozempic to lose weight, they're using it off-label, which is legal and common but changes how coverage and cost work.
Mounjaro vs Ozempic: side-by-side
| Mounjaro | Ozempic | |
|---|---|---|
| Molecule | Tirzepatide (dual GIP/GLP-1 agonist) | Semaglutide (GLP-1 agonist) |
| Maker | Eli Lilly | Novo Nordisk |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes; reducing cardiovascular risk |
| Form & frequency | Once-weekly injection | Once-weekly injection |
| Maximum dose | Up to 15 mg | Up to 2 mg |
| A1c & weight effects | Greater A1c and weight reduction vs semaglutide in SURPASS-2 | Strong A1c and weight reduction; bettered by tirzepatide in the head-to-head |
| Off-label weight use | Common | Common |
| Cost / coverage | Varies widely; verify current details | Varies widely; verify current details |
As with any tirzepatide-vs-semaglutide comparison, the milligram maximums (15 mg vs 2 mg) aren't apples-to-apples — they're different molecules on different scales. Judge them by outcomes, not dose numbers.
The head-to-head evidence: SURPASS-2
Unlike the weight-loss comparison between Zepbound and Wegovy — which relies on separate trials — diabetes gives us an actual head-to-head. In SURPASS-2, a 40-week randomized trial in adults with type 2 diabetes, all three tirzepatide doses produced greater reductions in A1c (a marker of average blood sugar) and greater weight loss than injectable semaglutide. It's the clearest direct evidence we have that, for glucose control and weight in diabetes, tirzepatide has the statistical edge on average.
"On average" is the operative phrase. A trial average doesn't tell you how you will respond, and it doesn't account for whether you can tolerate the drug or afford it. Some people do beautifully on Ozempic; some can't tolerate tirzepatide. The head-to-head result is one important input, not the whole decision.
What about weight loss?
Because both are used off-label for weight, this comes up constantly. In diabetes research, tirzepatide produced greater weight reduction than semaglutide — consistent with the broader pattern that tirzepatide averages higher weight loss across its trial programs. But if weight loss is the goal, it's worth knowing that the on-label, higher-dose products designed for that purpose are Zepbound (tirzepatide) and Wegovy (semaglutide). Our weight-loss guide explains why the approved indication matters for both results and coverage.
Which is right for you?
- Type 2 diabetes with blood sugar as the priority? Tirzepatide had the edge in the head-to-head, but semaglutide remains highly effective.
- Diabetes plus established heart disease? Ozempic's cardiovascular-risk approval may be relevant.
- Weight is the real target? Ask your clinician about the on-label weight-management products rather than an off-label route.
- Cost or coverage driving the decision? What your plan approves for your diagnosis may be the deciding factor.
This is education, not a recommendation. Both drugs are prescription-only and require a clinician who can weigh your history, tolerability and coverage. For the full lineup, see our GLP-1 medications guide.
Frequently asked questions
What's the difference between Mounjaro and Ozempic?
Mounjaro is tirzepatide, made by Eli Lilly, a dual GIP/GLP-1 receptor agonist. Ozempic is semaglutide, made by Novo Nordisk, a GLP-1 receptor agonist. Both are once-weekly injections FDA-approved for type 2 diabetes. The main difference is that tirzepatide acts on two gut-hormone receptors while semaglutide acts on one.
Is Mounjaro better than Ozempic?
In a head-to-head diabetes trial (SURPASS-2), tirzepatide produced greater A1c and weight reductions than semaglutide. That makes it more effective on average for those measures, but "better" also depends on tolerability, cost, insurance coverage and individual response. Only a clinician can decide which is appropriate for you.
Is Mounjaro or Ozempic better for weight loss?
Both Mounjaro and Ozempic are FDA-approved for type 2 diabetes, not weight loss, and both are used off-label for weight. In head-to-head diabetes research tirzepatide produced greater weight reduction than semaglutide. The dedicated weight-management approvals belong to their sibling brands — Zepbound (tirzepatide) and Wegovy (semaglutide).
Are Mounjaro and Ozempic the same?
No. They are different molecules from different companies. Mounjaro is tirzepatide (Eli Lilly) and Ozempic is semaglutide (Novo Nordisk). Both are once-weekly injections for type 2 diabetes and both act on the GLP-1 receptor, but tirzepatide additionally targets the GIP receptor, so they are not interchangeable.
Can you switch from Ozempic to Mounjaro?
Clinicians do transition patients between the two, but because they are different molecules dosed on different scales, you typically restart at a low dose of the new drug and titrate up rather than matching your old dose. Any switch should be planned and supervised by your prescriber.
Sources & further reading
- U.S. Food & Drug Administration — prescribing information for Mounjaro (tirzepatide) and Ozempic (semaglutide).
- SURPASS-2 trial, New England Journal of Medicine (2021) — tirzepatide vs semaglutide in type 2 diabetes.
- Eli Lilly and Novo Nordisk — manufacturer product and dosing information.